Spieker S, Löschmann P, Jentgens C, Boose A, Klockgether T, Dichgans J
Department of Neurology, University of Tübingen, Germany.
Clin Neuropharmacol. 1995 Jun;18(3):266-72.
The tremorlytic activity of the novel antiparkinson agent budipine was quantified in an open trial. Eleven patients with Parkinson's disease (PD) were treated with individual doses of budipine added to stable conventional antiparkinsonian medication. Tremor activity was measured using long-term electromyogram (EMG) recordings. Tremor intensity was reduced by 25%, tremor occurrence by 34%, and conventional "Unified Parkinson's Disease Rating Scale" (UPDRS) scores improved by 20% with this medication. There were two dropouts because of side effects. One dropout appeared not to be related to budipine. Apart from those, the drug was well tolerated by all patients. We conclude that budipine is an effective and well-tolerated tremorlytic drug and that the method of long-term EMG recording is suitable for tremor quantification in clinical studies.
在一项开放性试验中对新型抗帕金森药物布地品的震颤缓解活性进行了量化。11例帕金森病（PD）患者在稳定的常规抗帕金森药物基础上加用个体化剂量的布地品进行治疗。使用长期肌电图（EMG）记录来测量震颤活动。使用该药物后，震颤强度降低了25%，震颤发作次数减少了34%，传统的“统一帕金森病评定量表”（UPDRS）评分提高了20%。有2例患者因副作用退出试验。1例退出似乎与布地品无关。除此之外，所有患者对该药物耐受性良好。我们得出结论，布地品是一种有效且耐受性良好的震颤缓解药物，长期EMG记录方法适用于临床研究中的震颤量化。
